[{"id":"6606638f-85e0-45a0-a871-7812ab59024d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00878423","created_at":"2021-01-18T03:21:30.390Z","updated_at":"2024-07-02T16:36:51.244Z","phase":"Phase 1","brief_title":"Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors","source_id_and_acronym":"NCT00878423","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e onalespib (AT13387)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2020-01-18"},{"id":"59732630-1323-4010-b3db-8aa0e219e383","acronym":"","url":"https://clinicaltrials.gov/study/NCT01246102","created_at":"2021-01-18T08:40:06.980Z","updated_at":"2024-07-02T16:37:09.226Z","phase":"Phase 1","brief_title":"AT13387 in Adults With Refractory Solid Tumors","source_id_and_acronym":"NCT01246102","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HSP90AA1","pipe":"","alterations":" ","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e onalespib (AT13387)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 11/19/2010","start_date":" 11/19/2010","primary_txt":" Primary completion: 12/30/2013","primary_completion_date":" 12/30/2013","study_txt":" Completion: 10/27/2017","study_completion_date":" 10/27/2017","last_update_posted":"2018-07-05"},{"id":"d66807dc-cc75-441d-8ebe-a286f5e5eb6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01712217","created_at":"2021-01-18T07:27:40.966Z","updated_at":"2024-07-02T16:37:14.689Z","phase":"Phase 1/2","brief_title":"A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib","source_id_and_acronym":"NCT01712217","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • onalespib (AT13387)"],"overall_status":"Completed","enrollment":" Enrollment 220","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 05/16/2017","study_completion_date":" 05/16/2017","last_update_posted":"2018-01-19"},{"id":"78a5dedf-4f16-4fbe-a321-02ed38ac3d59","acronym":"","url":"https://clinicaltrials.gov/study/NCT01245218","created_at":"2021-01-18T05:00:54.263Z","updated_at":"2024-07-02T16:37:16.769Z","phase":"Phase 1","brief_title":"AT13387 in Treating Patients With Refractory Solid Tumors","source_id_and_acronym":"NCT01245218","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • HSP90AA1","pipe":"","alterations":" ","tags":["HER-2 • HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e onalespib (AT13387)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 08/01/2011","primary_completion_date":" 08/01/2011","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-31"}]